Selection and characterization of human antibodies against hepatitis B virus surface antigen (HBsAg) by phage-display

Hybridoma and Hybridomics

Volumn 21, Issue 5, 2002, Pages 385-392

  Kim, Se Ho ^a   Park, Song Yong ^a  

^a Antibody Engineering Laboratory   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ANTIBODY AFFINITY; ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CLONOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; ESCHERICHIA COLI; HEPATITIS B VIRUS; HUMAN; IMMUNOGLOBULIN STRUCTURE; NONHUMAN; NORMAL HUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

ESCHERICHIA COLI; HEPATITIS B VIRUS;

EID: 0036933042     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685902761022742     Document Type: Article

References (28)

1. Gitlin N: Hepatitis B: Diagnosis, prevention, and treatment. Clin Chem 1997;43:1500-1506.
2. Chisari FV, and Ferrari C: Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995;17:261-281.
3. Lok AS: Hepatitis B infection: Pathogenesis and management. J Hepatol 2000;32:89-97.
4. Heijtink R, Paulij W, van Bergen P, van Roosmalen M, Rohm D, Eichentopf B, Muchmore E, de Man R, and Osterhaus A: In vivo activity of a mixture of two human monoclonal antibodies (antiHB s) in a chronic hepatitis B virus carder chimpanzee. J Gen Virol 1999;80:1529-1535.
5. Keller MA, and Stiehm ER: Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000;13: 602-614.
6. Mountain A, and Adair JR: Engineering antibodies for therapy. Biotechnol Genet Eng Rev 1992;10:1-142.
7. Vaswani SK, and Hamilton RG: Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol 1998;81:105-119.
8. Reichert JM: Monoclonal antibodies in the clinic. Nat Biotechnol 2001;19:819-822.
9. Hoogenboom HR, and Chames P: Natural and designer binding sites made by phage display technology. Immunol Today 2000;21:371-378.
10. Green LL: Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods 1999;231:11-23.
11. Reisner Y, and Dagan S: The Trimera mouse: Generating human monoclonal antibodies and an animal model for human diseases. Trends Biotechnol 1998;16:242-246.
12. Nguyen H, Sandhu J, and Hozumi N: Production of human monoclonal antibodies in SCID mouse. Microbiol Immunol 1997;41:901-907.
13. Smith GP: Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 1985;228:1315-1317.
14. Winter G, Griffiths AD, Hawkins RE, and Hoogenboom HR: Making antibodies by phage display technology. Annu Rev Immunol 1994;12:433-455.
15. Burton DR, and Barbas CF: Human antibodies from combinatorial libraries. Adv Immunol 1994;57:191-280.
16. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P, de Bruine AP, Arends JW, and Hoogenboom HR: A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 1999;274:18218-18230.
17. Watkins NA, and Ouwehand WH: Introduction to antibody engineering and phage display. Vox Sang 2000;78:72-79.
18. Engberg J, Andersen PS, Nielsen LK, Dziegiel M, Johansen LK, and Albrechtsen B: Phage-display libraries of murine and human antibody Fab fragments. Mol Biotechnol 1996;6:287-310.
19. Kim SH, Titlow CC, and Margolies MN: An approach for preventing recombination-deletion of the 40-50 anti-digoxin antibody V(H) gene from the phage display vector pComb3. Gene 2000;241:19-25.
20. Kim SH, Song SH, Kim YJ, and Park SY: Expression and characterization of a recombinant Fab fragment derived from an antihuman alpha-fetoprotein monoclonal antibody. Mol Cells 2001;11:158-163.
21. Kim SH, Chun JH, and Park SY: Characterization of monoclonal antibodies against carcinoembryonic antigen (CEA) and expression in E. coli. Hybridoma 2001;20:265-272.
22. Kabat EA, Wu TT, Perry HM, Gottesman KS, and Foeller C: Sequences of Proteins of Immunological Interest. NIH Publication No. 91-3242, 5th Ed. US Department of Health and Human Services, Bethesda, MD, 1991.
23. Little M, Welschof M, Braunagel M, Hermes I, Christ C, Keller A, Rohrbach P, Kurschner T, Schmidt S, Kleist C, and Terness P: Generation of a large complex antibody library from multiple donors. J Immunol Methods 1999;231:3-9.
24. Gavilondo JV, and Larrick JW: Antibody engineering at the millennium. Biotechniques 2000;29:128-145.
25. Zebedee SL, Barbas CF III, Hom YL, Caothien RH, Graft R, DeGraw J, Pyati J, LaPolla R, Burton DR, Lerner RA, and Thornton GB: Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Natl Acad Sci U S A 1992;89:3175-3179.
26. Ogata N, Ostberg L, Ehrlich PH, Wong DC, Miller RH, and Purcell RH: Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci USA 1993;90:3014-3018.
27. Chothia C, and Lesk AM: Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 1987;196:901-917.
28. Duenas M, Malmborg AC, Casalvilla R, Ohlin M, and Borrebaeck CA: Selection of phage displayed antibodies based on kinetic constants. Mol Immunol 1996;33:279-285.